Uinta Bio, Inc.
Publicly observedPark City, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Park City | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Uinta Bio, Inc. | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | R388ZHWHYMA3 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant14 Sept 2026Publicly observed
NIH SBIR/STTR award: Novel combination immunotherapy with oncolytic adenovirus and immune checkpoint inhibitors for pancreatic ductal adenocarcinoma.
USD 306,388.00 · National Cancer Institute · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.